AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02592590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group C
Description: This condition receives two study components:~1. The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.~2. The second is the points-based feedback module. For each action in the app (e.g., viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser). As the intervention is goal drive, these participants will also receive printed goal setting worksheets.
Study NCT02592590 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group D
Description: This condition receives only the base-level smartphone app. This contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback. As the intervention is goal drive, these participants will also receive printed goal setting worksheets.
Study NCT02538224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5%ketoprofen gel + 3 % doxycycline
Description: GroupA:(0.05cc, mixed gel) be put into the periodontal pocket using an insulin syringe.~Intervention category Treatment: drugs
Study NCT02538224 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: :2.5%ketoprofen gel
Description: GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .
Study NCT02538224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: :2.5%ketoprofen gel
Description: GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .
Study NCT00331097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 35 mg/m2 intravenously on days 1, 8, and 15 every 28 days
Study NCT00331097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 600 mg/m2 intravenously days 1, 8 every 28 days
Study NCT00331097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: 40 mg/m2 intravenously days 1 and 8 every 28 days
Study NCT00331097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 600 mg/m2 intravenously days 1 and 8 every 28 days
Study NCT02434406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet-What Am I Worried About
Description: This web-based intervention consists of three sections: 1) Is this for me? 2) Practice 3) Understanding. The three main sections are divided up into nine sessions. Participants will get access to the program for eight weeks and can access the sessions more than once. Sessions are made up of multimedia presentations and worksheets that are completed online.
Study NCT01534702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine, cytarabine, idarubicin
Description: Treatment is stratified according to patients age (\< 60 years vs. ≥ 60 years).~Medication:~Patients \< 60 years:~* idarubicin 7.5 mg/m2 iv, days 1 + 3~* cytarabine 750 mg/m2 iv, days 1 to 5~Patients ≥ 60 years:~* idarubicine 6 mg/m2 iv, days 1 + 3~* cytarabine 750 mg/m2 iv, days 1 to 5~Clofarabine will be given in escalating doses to cohorts of at least three patients:~Clofarabine:~* level -1: 15 mg/m2 iv, days 1 to 5~* level 1: 20 mg/m2 iv, days 1 to 5~* level 2: 25 mg/m2 iv, days 1 to 5~* level 3: 30 mg/m2 iv, days 1 to 5~* level 4: 35 mg/m2 iv, days 1 to 5~Patients will be recruited according to a 3+3 design. New cohorts will be initiated depending on toxicity of the previous cohort during the first induction cycle. Enrollment will begin with dose level 1.
Study NCT05488535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cochlear implant headpiece
Description: investigational cochlear implant headpiece
Study NCT04558034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: cryotherapy will be delivered
Study NCT00914316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine, 1000 mg, capsule, twice daily, by mouth.
Study NCT00914316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily
Study NCT00914316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: twice daily
Study NCT02979496 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 0 g pomace (control)
Description: 16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded)
Study NCT02979496 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 90 g pomace
Description: 16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
Study NCT02979496 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 180 g pomace
Description: 16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
Study NCT02979496 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Flavored water (control)
Description: 16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
Study NCT02352389 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Blood samples will be drawn and analyzed at Day 0, 7, 14, 21, and 28
Study NCT02352389 — intervention group
Intervention type: OTHER
Intervention: Nasal swab
Description: Obtained on Day 0, 7, 14, 21 and 28.
Study NCT02352389 — intervention group
Intervention type: OTHER
Intervention: Oropharyngeal swab
Description: Obtained on Day 0, 7, 14, 21 and 28.
Study NCT02352389 — intervention group
Intervention type: OTHER
Intervention: Stool sample
Description: Obtained on Day 0, 7, 14, 21 and 28.
Study NCT02352389 — intervention group
Intervention type: OTHER
Intervention: Symptom checklist
Description: Obtained on Day 0, 7, 14, 21 and 28.
Study NCT00865566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA plasmid vaccine
Description: 4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
Study NCT00865566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant adenoviral serotype 5 (rAD5) vector vaccine
Description: 1 x 10\^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid
Study NCT00865566 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DNA vaccine placebo
Description: 1 mL IM via Biojector® in either deltoid
Study NCT00865566 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HIV-1 recombinant adenovirus vaccine placebo
Description: 1 mL administered IM by needle and syringe in either deltoid
Study NCT02395471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge™ Cell Collection Device
Description: Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.
Study NCT02739061 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral group therapy
Description: Establish closed every collection of six or so patients structured group. Each group patients were treated for 12 times, once a week, 120 minutes at a time.~Treatment for 1 to 3 times to obsessive-compulsive disorder and cognitive behavioral therapy as the theme of psychological education; 4 to 6, 8 to 10 times exposed step by step and reaction treatment and prevention of training;7 and 11 times invite patients family members or other caregivers, make education about obsessive-compulsive disorder cognitive behavioural therapy, to promote patients exposed response prevention homework completion and social support; The 12th time treatment is self assessment and treatment guidelines for a long time.
Study NCT02739061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sertraline, fluvoxamine
Description: Select specified drugs (sertraline, fluvoxamine)
Study NCT02739061 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral group therapy and drug therapy
Description: Select specified drugs (sertraline, fluvoxamine) and start group cognitive behavior therapy for 12 weeks at the same time
Study NCT00604799 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Talent Thoracic Stent Graft
Description: TEVAR
Study NCT00604799 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Talent Thoracic Stent Graft
Description: TEVAR
Study NCT00588835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant
Description: 125mg on Day 1; 80mg on Day 2-3 during CE cycle. Dexamethasone is added as well.
Study NCT00588835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone and Ondansetron during CE-treatment
Description: Standard anti-emetic regimen during CE treatment
Study NCT01887483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vetal Laban active
Description: Dairy product with probiotic
Study NCT01887483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dairy product without probiotic
Study NCT04204525 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative sensory testing
Description: Electrical detection and pain thresholds will be determined (at the sural nerve of the dominant leg and at the median nerve of both arms) with a constant current electrical stimulator.~Endogenous pain facilitation will be assessed by a temporal summation paradigm by delivering 20 electrical stimuli at the intensity of the electrical pain threshold.~Endogenous pain inhibition will be assessed by a conditioned pain modulation paradigm with electrical stimulation as test stimulus and the cold pressor test as conditioning stimulus.~EEG measurements with be performed with scalp EEG with 32 surface Sn electrodes in a headcap in referential montage following the standard 10-20 recording system.~A 5 minute resting state measurement will be performed with eyes closed, followed by EEG measurements during the condition pain modulation paradigm to assess the evoked-related potentials.
Study NCT01241201 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Priobiotic supplement VSL#3
Description: four weeks, twice daily two sachets of VSL#3, a priobitics mixture
Study NCT00970996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 250 mg/m\^2 by mouth on days 1, 2, and 3 of each 21-day cycle.
Study NCT00970996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 100 mg/m\^2 given in a short intravenous infusion 1 hour after completion of Temozolomide and a 2nd dose of 70 mg/m\^2 given on day 5 of each 21-day cycle.
Study NCT00970996 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20 mg/m\^2 intravenously on days 1, 2, 3, and 4 delivered immediately after Abraxane of each 21-day cycle.
Study NCT00970996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: 9 MIU/m\^2 in a continuous intravenous infusion over 24 hours on days 1, 2, 3, and 4 (total of 96 hours) beginning after completion of Cisplatin of each 21-day cycle.
Study NCT00970996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b
Description: 5 MIU/m\^2 in subcutaneous injection on days 1, 2, 3, 4, and 5 of each 21-day cycle.
Study NCT03584789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: A clinical decision support system designed to assist dentists in providing optimal pain management for patients without resorting to opioids when a non-opioid alternative would suffice. It provides pertinent clinical information to the dentist, including point-of-care access to the Prescription Drug Monitoring Program.
Study NCT03584789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Description: Patient education regarding pain management before and after dental extraction, including information about the risks and benefits of various strategies.
Study NCT00598676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biodegradable polymer Rapamycin-eluting stent
Description: due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
Study NCT00598676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: permanent polymer rapamycin-eluting stent (Cypher)
Description: due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
Study NCT00598676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: permanent polymer everolimus-eluting stent (Xience, Promus)
Description: due to randomization, everolimus-eluting stent with permanent polymer will be implanted
Study NCT00467116 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400mg/m2 initial dose week 1; followed by 250mg/m2/weekly starting week 2 with gemcitabine at fixed dose rate (10 mg/m2/min) + XRT. Cetuximab will start 1 week prior to all other treatment.
Study NCT00467116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Dose Level Gemcitabine dose Gemcitabine infusion~-1 150mg/m2 15 Minutes 0 200mg/m2 20 minutes~1. 300mg/m2 30 minutes~2. 400mg/m2 40 minutes
Study NCT00467116 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 50.4 Gy, 28 fractions, 5.5 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to encompass gross disease with a margin of 1-1.5 cm.~The prescription point will be designated at the intersection of the multiple beams.~There are no planned interruptions > 3 days.
Study NCT00529867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether/lumefantrine tablets
Description: Artemether/lumefantrine tablets containing 20mg artemether and 120mg lumefantrine~Dosage: 5 - 14.9 kg: 1 tablet and 15 - 24.9 kg: 2 tablets~Administered at 0, 8, 24, 36, 48, and 60 hours on days 0, 1, and 2
Study NCT00529867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether/Lumefantrine suspension
Description: Artemether/lumefantrine suspension containing 15mg artemether and 90mg lumefantrine per 5ml suspension~Dosage: 5.0 - 7.4 kg = 7 ml, 7.5 - 9.9 kg = 10 ml, 10 - 12.4 kg = 14 ml, 12.5 - 14.9 kg = 17 ml, 15 - 17.4 kg = 20 ml, 17.5 - 19.9 kg = 24 ml, 20 - 22.4 kg = 27 ml and 22.5 - 24.9 kg = 30 ml~Administered once daily at 0, 24, and 48 hours on days 0, 1 and 2
Study NCT04782583 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: questionnaire for the patients and the volontaire
Study NCT02215252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771 150 mg
Description: PF-05089771 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
Study NCT02215252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matched placebo for PF-05089771 150 mg and pregabalin 300 mg
Description: Matched placebo for PF-05089771 150 mg twice daily and pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
Study NCT02215252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Description: Pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
Study NCT02215252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771 150 mg + Pregabalin 300 mg
Description: PF-05089771 150 mg twice daily oral capsules with pregabalin 150 mg twice daily oral capsules. Treatment period = 4 weeks.
Study NCT02481661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: segmentectomy
Description: segmentectomy in Arm I and lobectomy in Arm II
Study NCT02481661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: segmentectomy
Description: segmentectomy in Arm I and lobectomy in Arm II
Study NCT01356628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: PD-0332991, 125mg, 3 cycles
Study NCT04264936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC and JS001
Description: Recombinant Humanized anti-HER2(Human epidermal growth factor receptor-2) Monoclonal Antibody-MMAE(Monomethyl Auristatin E) Conjugate For Injection and JS001 Injection
Study NCT03335670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Pentixafor
Description: 68Ga Pentixafor is a radiolabeled cyclic pentapeptide with high affinity for CXCR4 receptor
Study NCT03646552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THX-110
Description: Participants will receive THX-110 in the following regimen:~Dronabinol will be slowly titrated in the first 10 days of the study and PEA will be given in a constant dose of 800mg per day for the entire duration of the study.~Patients will be followed for a total of 30 days.
Study NCT03644004 — intervention group
Intervention type: OTHER
Intervention: frequency of diabetes mellitus, type 2, diagnosis in patients with medical history of gestational diabetes.
Description: Patients will be contacted by mail with sending of the information notice to ask them to participate in the study.~If they don't reply, the subjects will be called by phone by the investigator to collect their non opposition of participation at the study.~During this call, the investigator will be able to answer all the questions about the study.~The report of this telephone conversation will be register in the medical file of the patient.~Then, we will collect informatic data from the hospital concerning the patients.~After that they will be contacted by phone to answer a survey. Beside, another secure survey will be send by email to each patient's family doctor.~To finish, crossing data between those of the patients and the family doctor and anonymisation of the data.
Study NCT01717027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation A, single dose, taken whole and under fed conditions
Study NCT01717027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation J, single dose, taken whole and under fed conditions
Study NCT01717027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation K, single dose, taken whole and under fed conditions
Study NCT01717027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: One capsule of 40 mg PF-00345439 Formulation J or K, single dose, chewed and under fasted conditions
Study NCT04028219 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Online surveys
Description: Psychometric measures within 14 online surveys, which is one at each assessment point (before and 3, 6, 9, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120 months after hormonal therapy).
Study NCT01746901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution + Placebo ALO-02 (intact)
Study NCT01746901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intact ALO-02 60 mg/7.2 mg
Description: Placebo solution + ALO-02 60 mg/7.2 mg (intact)
Study NCT01746901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crushed ALO-02 60 mg/7.2 mg
Description: crushed ALO-02 60 mg/7.2 mg in solution + placebo ALO-02 (intact)
Study NCT01746901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: crushed oxycodone IR 60 mg
Description: crushed oxycodone immediate-release (IR) 60 mg in solution + placebo ALO-02 (intact)
Study NCT01746901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crushed ALO-02 40 mg/4.8 mg
Description: crushed ALO-02 40 mg/4.8 mg in solution + placebo ALO-02 (intact)
Study NCT01746901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: crushed oxycodone IR 40 mg
Description: crushed oxycodone immediate-release (IR) 40 mg in solution + placebo ALO-02 (intact)
Study NCT04063007 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ketogenic diet
Description: The patients follow the ordinary treatment protocol for ketogenic diet
Study NCT01351181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leaflet
Description: Advice Leaflet
Study NCT01351181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Advice
Description: Leaflet
Study NCT01351181 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Normal Care
Description: Normal Care
Study NCT00664625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: Capsules, Oral, Once Daily, Single Dose
Study NCT00664625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules, Oral, Once Daily, Single Dose
Study NCT02824341 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: fMRI
Study NCT00803569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine
Description: The vaccine comprises the modified canary pox vector, ALVAC(2), inserted with the following genes: NYESO-1(M), TRICOM (LFA-3, ICAM-1, B7.1), vvE3L, vvK3L. The vaccine is administered at a dose of 0.5 mL SC.
Study NCT00803569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: The GM-CSF sargramostim is administered at a dose of 100 μg SC.